Phenomex
PhenomeX is uniquely enabling the exploration of the phenome and mastery of single cells for all labs & scientiststhrough a simple and accessible workflow.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor | €0.0 Valuation: €0.0 1.4x EV/Revenue -1.1x EV/EBITDA | round | |
N/A | Spinout | ||
| Total Funding | 000k | ||
| USD | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 81 % | 13 % | 33 % | (8 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (54 %) | (18 %) | (62 %) | (83 %) | (119 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (75 %) | (32 %) | (65 %) | (84 %) | (125 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 93 % | 68 % | 73 % | 69 % | 68 % |
Source: Company filings or news article
Related Content
Phenomex, founded in 2021 by Sherine Chan and Vandon T Duong, operates at the intersection of biotechnology and single-cell biology. Chan, holding a Ph.D. in Cellular and Molecular Biology, and Duong, with a background in engineering, leveraged their combined expertise to address challenges in drug discovery. Their journey began with the recognition that traditional biological assays lacked the resolution to understand cellular heterogeneity, a critical factor in disease and treatment response. This insight led to the development of a technology platform designed to analyze individual cells at high throughput.
The company's core business revolves around providing advanced tools for functional cell biology. It targets researchers in academic institutions, pharmaceutical companies, and cancer centers. The business model is centered on selling proprietary high-throughput screening platforms and associated consumables. These tools empower scientists to gain deeper insights into cell function and behavior, which is crucial for the development of new therapies. By offering a detailed view of each cell, the platform accelerates the identification of effective drug candidates and the understanding of disease mechanisms.
Phenomex's key offering is a suite of instruments and services that provide high-resolution analysis of single cells at a rapid pace. This capability allows for the screening of millions of individual cells to identify those with desired functional characteristics, a significant step up from methods that analyze cell populations in bulk. A unique selling point is the ability to connect a cell's functional response directly to its genetic makeup. This is achieved by first identifying a cell of interest based on its function and then sequencing its genome or transcriptome, a process known as phenomics. This direct linkage is instrumental in advancing discoveries for the prevention and treatment of diseases.
Keywords: phenomics, single-cell analysis, functional cell biology, drug discovery, high-throughput screening, biotechnology, cellular heterogeneity, phenotyping, oncology research, cell-based assays